Form 4 for TNXP Tonix Pharmaceuticals Holding Corp.
Accepted 2026-07-09 09:05:31 ET · period of report 2026-06-30 · accession 0001493152-26-032615 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-09 09:05 | 2026-06-30 | TNXP | SAENGER BRADLEY | CFO | J - Other | $10.91 | +1,453 | 2,154 | +207% | +$15.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value | 2026-06-30 | J | A | 1,453 | $10.91 | 2,154 | D | — | — | (F1) Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan. |